MIR Q2 Deep Dive: Margin Expansion and Nuclear Backlog Growth Offset Revenue Miss
Radiation safety company Mirion (NYSE:MIR) missed Wall Street’s revenue expectations in Q2 CY2026, but sales rose 19.7% year on year to $266.8 million. Its non-GAAP profit of $0.12 per share was 17% above analysts’ consensus estimates.
Is now the time to buy MIR? Find out in our full research report (it’s free for active Edge members).
Mirion (MIR) Q2 CY2026 Highlights:
- Revenue: $266.8 million vs analyst estimates of $269.6 million (19.7% year-on-year growth, 1% miss)
- Adjusted EPS: $0.12 vs analyst estimates of $0.10 (17% beat)
- Adjusted EBITDA: $65.3 million vs analyst estimates of $62.78 million (24.5% margin, 4% beat)
- Management reiterated its full-year Adjusted EPS guidance of $0.52 at the midpoint
- EBITDA guidance for the full year is $292.5 million at the midpoint, above analyst estimates of $289.5 million
- Operating Margin: 6.7%, up from 4.6% in the same quarter last year
- Market Capitalization: $4.08 billion
StockStory’s Take
Mirion’s second quarter results were met with a negative market reaction, as revenue came in below Wall Street expectations despite a nearly 20% year-over-year increase. Management attributed the revenue outcome to mixed performance across its segments, with growth in nuclear power offset by declines in new build projects and delayed hardware demand in the medical segment. CEO Thomas D. Logan pointed to “expanding adjusted EBITDA margins from both operating segments and across the total enterprise,” highlighting the positive impact of product mix and pricing. The company also faced an unexpected contract cancellation in China, which management described as unusual but not indicative of broader risk to its backlog.
Looking ahead, Mirion’s guidance for the remainder of the year is shaped by expectations of accelerating organic growth and expanding margins, especially as easier comparisons and backlog conversion support higher second-half revenue. Management remains focused on execution within the nuclear power and medical segments, citing robust order momentum and a strong pipeline of large opportunities. CFO Brian Schopfer emphasized, “we have good visibility to the back end of the year,” noting that 81% of expected full-year revenue is already accounted for by the existing backlog, and new product launches like PlanAI are expected to contribute further. The company continues to invest in AI and operational efficiencies, aiming to strengthen its competitive positioning and margin profile.
Key Insights from Management’s Remarks
Management attributed the quarter’s results to ongoing nuclear power demand, strong order intake, and cost discipline, while revenue fell short of expectations due to delays in medical hardware and the timing of new build projects.
- Nuclear backlog expansion: Order momentum in the nuclear power segment continued, with Mirion’s total backlog rising nearly 40% year-over-year, driven by large wins in both the operating fleet and small modular reactor (SMR) projects.
- Medical segment headwinds: The medical division faced delayed hardware demand and tough comparisons from prior year hardware orders, resulting in flat to slightly negative organic growth. However, management noted strong order growth in nuclear medicine software and a more optimistic outlook for the second half.
- Margin improvement drivers: Adjusted EBITDA margins expanded across both segments, helped by favorable product mix, price increases, and operational improvements. Management also credited a modest benefit from tariff refunds and disciplined cost control.
- AI and digital initiatives: Mirion is investing in artificial intelligence to accelerate product development, automate internal processes, and enhance new product capabilities. Recent launches, such as the PlanAI dosimetry platform and Daily QA4 Pro, are designed to streamline workflows for customers in both nuclear and healthcare sectors.
- China contract cancellation: An $18 million contract for a Chinese new build project was canceled due to prolonged project delays and geopolitical tensions. Management described this as a rare event with immaterial impact on long-term guidance, while reaffirming confidence in the quality and durability of the overall backlog.
Drivers of Future Performance
Mirion’s forward-looking guidance is underpinned by backlog visibility, large opportunity wins in nuclear, and continued investment in AI and operational efficiency.
- Backlog-driven growth: Management expects the majority of second-half revenue to be supported by the existing backlog, with 81% of full-year revenue already covered. This backlog consists mainly of recurring business from the global installed base in nuclear power, as well as recently secured large projects.
- Nuclear and SMR momentum: The company anticipates double-digit organic growth in the nuclear power segment for the remainder of the year, with SMR projects expected to grow faster than the overall business. Management sees ongoing policy support and industry partnerships as key accelerators of this trend.
- Margin expansion and cost controls: Further margin improvement is anticipated as operating leverage increases and procurement efficiencies are realized. Investments in AI and organizational restructuring are expected to yield productivity gains, though management cautions that M&A activity and the pace of new build project conversions could introduce some variability in near-term results.
Catalysts in Upcoming Quarters
In upcoming quarters, our analysts will be watching (1) the pace of conversion from robust nuclear and SMR order backlog into revenue, (2) evidence that medical hardware demand and software momentum are translating into sustained growth, and (3) the impact of AI-driven product launches and operational improvements on margin expansion. Additionally, we will monitor M&A activity, backlog quality, and the resolution of any outstanding contract issues.
Mirion currently trades at $14.74, down from $16.79 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).
High Quality Stocks for All Market Conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.